Licoagroside B



Compound IDCDAMM02748
Common nameLicoagroside B
IUPAC name3-hydroxy-3-methyl-5-oxo-5-[[3,4,5-trihydroxy-6-(2-methyl-4-oxopyran-3-yl)oxyoxan-2-yl]methoxy]pentanoic acid
Molecular formulaC18H24O12

Experimental data

Retention time13.15
Adduct[M+H]+
Actual mz433.134
Theoretical mz433.134
Error0.64
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.0706

Identifiers and class information

Inchi keyWCVUIHQUPRXYKT-UHFFFAOYNA-N
SmilesO=C(O)CC(O)(C)CC(=O)OCC1OC(OC=2C(=O)C=COC2C)C(O)C(O)C1O
SuperclassLipids and lipid-like molecules
ClassSaccharolipids

Pharmacokinetic properties

Number of descriptor values(#stars)2
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)1
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)12
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)432.38
Computed dipole moment(dipole)10.077
Total solvent accessible surface area (SASA)683.498
Hydrophobic component of SASA (FOSA)277.826
Hydrophilic component of SASA (FISA)306.103
Pie component of the SASA (PISA)99.569
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1238.55
Number of hydrogen bond donors (donorHB)4
Number of hydrogen bond acceptors (accptHB)13.8
Free energy of solvation of dipole (dip^2/V)0.0819815
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0403805
Globularity descriptor (glob)0.816023
Predicted polarizability in cubic angstroms (QPpolrz)36.658
Predicted hexadecane/gas partition coefficient (QPlogPC16)13.501
Predicted octanol/gas partition coefficient (QPlogPoct)26.77
Predicted water/gas partition coefficient (QPlogPw)20.928
Predicted octanol/water partition coefficient (QPlogPo/w)-0.24
Predicted aqueous solubility (QPlogS)-2.42
Conformation-independent predicted aqueous solubility (CIQPlogS)-2.992
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-3.176
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)3.139
Predicted brain/blood partition coefficient (QPlogBB)-3.224
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)1.239
Predicted skin permeability, log Kp (QPlogKp)-5.658
PM3 calculated ionization potential (IP(ev))9.523
PM3 calculated electron affinity (EA(eV))0.298
Number of likely metabolic reactions (#metab)7
Prediction of binding to human serum albumin (QPlogKhsa)-1.136
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)21.473
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)210.592
Number of nitrogen and oxygen atoms (#NandO)12
Number of violations of Lipinski’s rule of five (RuleOfFive)1
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P22303ACHEAcetylcholinesteraseT30082SwissTargetPrediction
P29274ADORA2AAdenosine A2a receptorT77365SwissTargetPrediction
O43570CA12Carbonic anhydrase XIIT16987SwissTargetPrediction
P00918CA2Carbonic anhydrase IIT20401SwissTargetPrediction
P16083NQO2Quinone reductase 2T75498SwissTargetPrediction
P08913ADRA2AAlpha-2a adrenergic receptorT11448SwissTargetPrediction
Q04609FOLH1Glutamate carboxypeptidase IIT97071SwissTargetPrediction
P18825ADRA2CAdrenergic receptor alpha-2T01777SwissTargetPrediction
Q16539MAPK14MAP kinase p38 alphaT65864SwissTargetPrediction
P16109SELPP-selectinT10965SwissTargetPrediction
P60568IL2Interleukin-2T61698SEA
P12268IMPDH2Inosine-5'-monophosphate dehydrogenase 2T89360SwissTargetPrediction
P53350PLK1Serine/threonine-protein kinase PLK1T40694SwissTargetPrediction
P17931LGALS3Galectin-3T72038SwissTargetPrediction
P51812RPS6KA3Ribosomal protein S6 kinase alpha 3T03279SwissTargetPrediction
Q9NPH5NOX4NADPH oxidase 4T29741SwissTargetPrediction
Q9GZQ4NMUR2Neuromedin-U receptor 2T04210SwissTargetPrediction and SEA
Q9HC29NOD2Nucleotide-binding oligomerization domain-containing protein 2T75643SwissTargetPrediction
P43403ZAP70Tyrosine-protein kinase ZAP-70T64553SwissTargetPrediction
Q9NZ08ERAP1Endoplasmic reticulum aminopeptidase 1T72849SEA
P30837ALDH1B1Acetaldehyde dehydrogenaseT99641SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T30082DI0025Alzheimer disease[ICD-11: 8A20]P22303ACHE
T30082DI0166Glaucoma[ICD-11: 9C61]P22303ACHE
T30082DI0282Myasthenia gravis[ICD-11: 8C6Y]P22303ACHE
T30082DI0313Oesophageal/gastroduodenal disorder[ICD-11: DD90]P22303ACHE
T30082DI0332Pediculosis[ICD-11: 1G00]P22303ACHE
T30082DI0421Unspecific substance harmful effect[ICD-11: NE6Z]P22303ACHE
T77365DI0319Orthostatic hypotension[ICD-11: BA21]P29274ADORA2A
T77365DI0331Parkinsonism[ICD-11: 8A00]P29274ADORA2A
T77365DI0359Radionuclide imaging[ICD-11: N.A.]P29274ADORA2A
T16987DI0046Bacterial infection[ICD-11: 1A00-1C4Z]O43570CA12
T16987DI0372Seborrhoeic dermatitis[ICD-11: EA81]O43570CA12
T20401DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P00918CA2
T20401DI0137Essential hypertension[ICD-11: BA00]P00918CA2
T20401DI0166Glaucoma[ICD-11: 9C61]P00918CA2
T20401DI0175Heart failure[ICD-11: BD10-BD1Z]P00918CA2
T20401DI0214Insomnia[ICD-11: 7A00-7A0Z]P00918CA2
T20401DI0372Seborrhoeic dermatitis[ICD-11: EA81]P00918CA2
T75498DI0214Insomnia[ICD-11: 7A00-7A0Z]P16083NQO2
T11448DI0040Attention deficit hyperactivity disorder[ICD-11: 6A05]P08913ADRA2A
T11448DI0317Opioid use disorder[ICD-11: 6C43]P08913ADRA2A
T11448DI0396Substance abuse[ICD-11: 6C40]P08913ADRA2A
T97071DI0122Diagnostic imaging[ICD-11: N.A.]Q04609FOLH1
T97071DI0346Prostate cancer[ICD-11: 2C82]Q04609FOLH1
T01777DI0166Glaucoma[ICD-11: 9C61]P18825ADRA2C
T01777DI0190Hypertension[ICD-11: BA00-BA04]P18825ADRA2C
T01777DI0196Hypotension[ICD-11: BA20-BA21]P18825ADRA2C
T01777DI0308Obesity[ICD-11: 5B80-5B81]P18825ADRA2C
T01777DI0310Ocular disease[ICD-11: N.A.]P18825ADRA2C
T01777DI0396Substance abuse[ICD-11: 6C40]P18825ADRA2C
T65864DI0102Coronary atherosclerosis[ICD-11: BA52]Q16539MAPK14
T65864DI0287Myocardial infarction[ICD-11: BA41-BA43]Q16539MAPK14
T65864DI0366Rheumatoid arthritis[ICD-11: FA20]Q16539MAPK14
T65864DI0437Vitamin deficiency[ICD-11: 5B55-5B5F]Q16539MAPK14
T10965DI0088Circulatory system disease[ICD-11: BE2Z]P16109SELP
T10965DI0381Sickle-cell disorder[ICD-11: 3A51]P16109SELP
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T89360DI0413Transplant rejection[ICD-11: NE84]P12268IMPDH2
T40694DI0012Acute myeloid leukaemia[ICD-11: 2A60]P53350PLK1
T40694DI0284Myelodysplastic syndrome[ICD-11: 2A37]P53350PLK1
T40694DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P53350PLK1
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T03279DI0249Mature B-cell leukaemia[ICD-11: 2A82]P51812RPS6KA3
T29741DI0146Fibrosis[ICD-11: GA14-GC01]Q9NPH5NOX4
T75643DI0120Diabetes mellitus[ICD-11: 5A10]Q9HC29NOD2
T75643DI0179Hepatitis virus infection[ICD-11: 1E50-1E51]Q9HC29NOD2
T99641DI0396Substance abuse[ICD-11: 6C40]P30837ALDH1B1

Copyright © 2025